[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Pages 23012-23013]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10153]



[[Page 23012]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Patent License: Chimeric L1/L2 
Protein and Virus-Like Particles Based Human Papillomavirus Vaccines

AGENCY: National Institutes of Health, Department of Health and Human 
Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an exclusive patent license to practice the 
inventions embodied in the U.S. Patents and Patent Applications listed 
in the Supplementary Information section of this notice to PathoVax, 
LLC located in Baltimore, MD.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before June 5, 2017 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated exclusive license should be 
directed to: Kevin W. Chang, Ph.D., Senior Technology Transfer Manager, 
NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 
9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-
9702 Telephone: (240)-276-6910; Facsimile: (240)-276-5504 Email: 
[email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

    United States Provisional Patent Application No. 60/649,249 filed 
February 1, 2005 and entitled, ``Papillomavirus L2 N-terminal Peptides 
For The Induction Of Broadly Cross-neutralizing Antibodies'' [HHS 
Reference No. E-103-2005/0-US-01]; United States Provisional Patent 
Application No. 60/697,655 filed July 7, 2005 and entitled, 
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly 
Cross-neutralizing Antibodies'' [HHS Reference No. E-103-2005/1-US-01]; 
United States Provisional Patent Application No. 60/752,268 filed 
December 21, 2005 and entitled, ``Papillomavirus L2 N-terminal Peptides 
For The Induction Of Broadly Cross-neutralizing Antibodies'' [HHS 
Reference No. E-103-2005/2-US-01]; International PCT Application No. 
PCT/US2006/003601 filed February 1, 2006, and entitled, 
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly 
Cross-neutralizing Antibodies'' [HHS Reference No. E-103-2005/3-PCT-
01]; United States Patent No. 8,404,244, issued March 26, 2013 and 
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of 
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-US-
02]; United States Patent No. 9,388,221 issued July 12, 2016 and 
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of 
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-US-
10]; Canadian Patent Application No. 2,596,698 filed February 1, 2006 
and entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction 
Of Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-
CA-03]; Australian Patent No. 2006210792 issued November 8, 2012 and 
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of 
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-AU-
04]; Japanese Patent No. 5224821 issued March 22, 2013 and entitled, 
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly 
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-JP-05]; 
Brazilian Patent Application No. PI0607097-3 filed February 1, 2006 and 
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of 
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-BR-
06]; Chinese Patent No. 200680011079.1 issued March 27, 2013 and 
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of 
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-CN-
07]; Indian Patent No. 263255 issued October 16, 2014 and entitled, 
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly 
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-IN-08]; 
European Patent No. 1853307 issued December 14, 2016 and entitled, 
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly 
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-EP-09]; 
German Patent No. 1853307 issued December 14, 2016 and entitled, 
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly 
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-DE-11]; 
French Patent No. 1853307 issued December 14, 2016 and entitled, 
``Papillomavirus L2 N-terminal Peptides For The Induction Of Broadly 
Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-FR-12]; and 
United Kingdom Patent No. 1853307 issued December 14, 2016 and 
entitled, ``Papillomavirus L2 N-terminal Peptides For The Induction Of 
Broadly Cross-neutralizing Antibodies'' [HHS Ref. No. E-103-2005/3-GB-
13]. The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of Licensed Patent Rights 
for the following: ``Use of Human Papillomavirus Virus (HPV) L1/L2 
chimeric proteins and Virus Like Particles (VLPs) for the prevention 
and/or treatment of cutaneous, mucosal HPV infections and diseases.''
    The subject technologies are papillomavirus L2 capsid protein based 
vaccines against HPV. The L2 protein is the minor papillomavirus capsid 
protein for papillomaviruses. It is known that antibodies to this 
protein can neutralize homologous infection. Furthermore, L2 proteins 
can induce cross-neutralizing antibodies. Specifically, epitopes at the 
N-terminus of L2 shared by cutaneous and mucosal types of 
papillomavirus types and by types that infect divergent species are 
broadly cross-neutralizing. These epitopes at the N-terminus of L2 can 
be used to elicit cross-neutralizing antibodies against different types 
of HPV.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Exclusive Patent License Agreement. 
Comments and objections submitted to this notice will not be made 
available for public inspection and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.


[[Page 23013]]


    Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2017-10153 Filed 5-18-17; 8:45 am]
 BILLING CODE 4140-01-P